This over-the-counter product is used for the reduction and control of gastrointestinal symptoms that are produced by excessive acid secretion and is also helpful in the treatment of gastritis, heartburn, reflux and esophagitis. It is based on a molecule that allows for faster absorption than that of Omeoprazol.
With this acquisition, Genomma Lab complements its line of anti-acid products, in particular its product Genoprazol. This is said to be Genomma’s first acquisition since listing on the Mexican Stock Exchange in June 2008, when it raised capital seeking to accelerate growth.